Free Trial

Alterity Therapeutics (ATHE) Competitors

Alterity Therapeutics logo
$4.04 -0.01 (-0.12%)
Closing price 07/3/2025 01:19 PM Eastern
Extended Trading
$4.02 -0.02 (-0.47%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATHE vs. ALEC, ACOG, INMB, ACTU, CGEN, FATE, KYTX, BDTX, VXRT, and LXEO

Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Alector (ALEC), Alpha Cognition (ACOG), INmune Bio (INMB), Actuate Therapeutics (ACTU), Compugen (CGEN), Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry.

Alterity Therapeutics vs. Its Competitors

Alterity Therapeutics (NASDAQ:ATHE) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 9.1% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alterity Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Alterity Therapeutics has a net margin of 0.00% compared to Alector's net margin of -139.74%. Alterity Therapeutics' return on equity of 0.00% beat Alector's return on equity.

Company Net Margins Return on Equity Return on Assets
Alterity TherapeuticsN/A N/A N/A
Alector -139.74%-100.58%-25.15%

In the previous week, Alector had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 1 mentions for Alector and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.00 equaled Alector'saverage media sentiment score.

Company Overall Sentiment
Alterity Therapeutics Neutral
Alector Neutral

Alterity Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 197.40%. Alector has a consensus price target of $4.00, indicating a potential upside of 171.19%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alterity Therapeutics is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alterity Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Alector
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14

Alterity Therapeutics has higher earnings, but lower revenue than Alector.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alterity TherapeuticsN/AN/A-$12.54MN/AN/A
Alector$100.56M1.47-$119.05M-$1.26-1.17

Summary

Alterity Therapeutics beats Alector on 7 of the 12 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHE vs. The Competition

MetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$35.79M$2.89B$5.53B$9.02B
Dividend YieldN/A2.44%5.22%3.99%
P/E RatioN/A21.7127.7920.25
Price / SalesN/A283.26430.22119.26
Price / CashN/A41.7026.2128.59
Price / Book3.887.538.035.65
Net Income-$12.54M-$55.14M$3.18B$249.15M
7 Day Performance-1.34%4.22%2.88%2.91%
1 Month Performance-14.69%0.91%1.67%4.11%
1 Year Performance120.81%5.40%34.26%20.98%

Alterity Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHE
Alterity Therapeutics
2.6279 of 5 stars
$4.04
-0.1%
$12.00
+197.4%
+120.8%$35.79MN/A0.0010Gap Down
ALEC
Alector
3.845 of 5 stars
$1.38
-6.5%
$4.00
+190.9%
-66.4%$146.99M$88.34M-1.09270
ACOG
Alpha Cognition
1.6937 of 5 stars
$9.00
-1.7%
$20.00
+122.2%
N/A$146.74MN/A-7.50N/APositive News
INMB
INmune Bio
1.5861 of 5 stars
$6.22
-2.5%
$22.80
+266.6%
-66.7%$146.64M$50K-3.2210Gap Down
High Trading Volume
ACTU
Actuate Therapeutics
3.0009 of 5 stars
$7.05
-5.6%
$20.50
+190.8%
N/A$146.56MN/A0.0010Positive News
CGEN
Compugen
1.5373 of 5 stars
$1.63
-0.6%
$4.00
+145.4%
+14.1%$146.35M$27.59M-10.1970Positive News
FATE
Fate Therapeutics
4.2704 of 5 stars
$1.14
-4.2%
$3.83
+236.3%
-63.9%$136.38M$13.63M-0.77550Analyst Revision
KYTX
Kyverna Therapeutics
1.2786 of 5 stars
$3.22
+4.9%
$18.50
+474.5%
-58.7%$132.68M$7.03M-0.9596Gap Down
BDTX
Black Diamond Therapeutics
3.1269 of 5 stars
$2.27
-2.6%
$14.60
+543.2%
-42.3%$132.49MN/A37.8390Positive News
VXRT
Vaxart
2.2589 of 5 stars
$0.56
-3.4%
$3.00
+435.3%
-34.4%$132.42M$28.70M-2.08120
LXEO
Lexeo Therapeutics
1.8847 of 5 stars
$3.96
+1.3%
$16.60
+319.2%
-71.4%$129.80M$650K-1.2058

Related Companies and Tools


This page (NASDAQ:ATHE) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners